The Future Use of in Vitro Data in Risk Assessment to Set Human Exposure Standards: Challenging Problems and Familiar Solutions by Crump, Kenny S. et al.
1350  v o l u m e  118 | n u m b e r 10 | October 2010  •  Environmental Health Perspectives
Commentary
The Committee on Toxicity Testing and 
Assessment of Environmental Agents of the 
National Research Council (NRC 2007) envi-
sioned a future for toxicity testing  that moves 
from testing in whole animals toward in vitro 
assays conducted in human cells. The vision 
is anchored to the development of a suite of 
high-throughput assays for “toxicity path-
ways,” which are normal biological signaling 
pathways that when sufficiently perturbed can 
lead to adverse effects in humans. Developing 
these assays would be supported by mecha-
nistic computational models that describe the 
biological circuitry of the pathways. Exposure 
standards for toxic chemicals would be deter-
mined using data from these assays, coupled 
with physiologically based pharmacokinetic 
(PBPK) models that predict amounts of chemi-
cal reaching cell or protein targets from spe-
cific patterns of human exposure, to estimate 
human exposures that would not cause biolog-
ically significant perturbations of these path-
ways (Andersen and Krewski 2009; Collins 
et al. 2008; Krewski et al. 2008; NRC 2007).
The committee envisioned that in vitro 
methods will eventually largely or even totally 
supplant the need for toxicity testing in whole 
animals. Once in place, these methods are pro-
jected to enable toxicity testing to be conducted 
much more quickly and cheaply than conven-
tional testing in whole animals, which will help 
to alleviate the large backlog of chemicals that 
have not been adequately tested. However, 
implementing this vision will require a large 
commitment of resources, and the benefits to 
regulation of toxic substances may be small in 
the near term. The number of toxicity pathways 
(TPs) for which assays will be needed has been 
estimated as high as 200, and the level of effort 
required to “map” these pathways has been 
compared with that required to map the human 
genome. Developing and validating assays for 
these pathways have been estimated to require 
$1–2 billion over the next decade or two, and a 
new national institute with an annual budget on 
the order of $100 million has been proposed to 
spearhead this under  taking (Stokstad 2009).
In this commentary, we present our views 
on how various elements of the NRC vision 
can be used to develop quantitative risk assess-
ments for toxic chemicals. As plans to bring 
the NRC vision to life are being developed, 
the clearer the identification of the direction 
needed and of the end product, the more likely 
it is that the eventual product will be maxi-
mally useful and developed in a timely and 
cost-effective manner. The ideas and sugges-
tions in this commentary are offered toward 
these goals. We focus on issues that can have a 
major impact on methods for quantitative risk 
assessment from in vitro data but that have not 
been given sufficient scrutiny up to now. These 
issues are largely statistical in nature, and we 
believe will be present in virtually any method 
for quantitative risk assessment that is based on 
in vitro data.
Discussions
The NRC vision is predicated upon gaining a 
thorough understanding of TPs and develop-
ing in vitro assays that can be used to test for 
perturbations in TPs. A number of challenging 
technical problems must be overcome in devel-
oping these assays, including developing in vitro 
methods that can be applied to volatile chemi-
cals, addressing effects that take an extended 
time to develop (including trans  generational 
effects), accounting for metabolism and 
addressing cross-cellular and cross-organ feed-
back signaling (Andersen and Krewski 2009; 
Conolly 2009; Hattis 2009; Tsuji 2009). Here 
we make the optimistic assumptions that these 
problems have been resolved and that in vitro 
assays are available for all important pathways 
in humans. We focus on issues that must be 
faced in basing quantitative risk assessments on 
these assays. Likewise, whereas the NRC vision 
projects that targeted testing in whole animals 
will be needed for some time to come, for sim-
plicity the present discussion is limited to use of 
in vitro data.
Although the NRC committee did not 
define what it meant by an exposure that 
does not lead to “biologically significant per-
turbations,” this clearly will be a key issue in 
implementing the NRC vision. We see four 
possible definitions: a) an exposure that does 
not result in any biochemical or genomic 
perturbation of any pathway having adverse 
sequelae; b) an exposure that causes some 
genomic or biochemical perturbation in such 
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a pathway but does not result in change to 
any downstream cellular response; c) an expo-
sure that causes some genomic or biochemical 
perturbation that results in a change in some 
downstream cellular response but that does 
not increase apical risk; or d) an exposure that 
causes perturbations of these pathways that 
results in some increase in apical risk, but the 
amount of increase is not considered to be 
biologically significant. The last interpreta-
tion seems inadequate, because “biologically 
significant,” however it is defined, is too lim-
ited a rubric for determining whether a given 
increase in risk is acceptable to society. The 
remaining three possibilities all involve some 
type of threshold of exposure below which 
there is no effect upon an apical response, with 
the threshold occurring at the biochemical or 
genomic level, the cellular level, or the level 
of the apical response. So, although not stated 
explicitly by the NRC committee, its vision 
appears to tacitly incorporate the notion of an 
exposure threshold for an apical effect.
Viewed in this way, several issues come to 
mind. First of all, there is no guarantee that a 
threshold dose will exist for a particular api-
cal response. Typically, in a large population, 
there will be a distribution of background 
responses for an upstream (e.g., biochemi-
cal, genomic, or cellular) event in a given 
pathway, and the tail of this distribution can 
include values that are associated with adverse 
apical responses that occur in the absence of 
exposure to a toxic substance. Consequently, 
the change in an upstream response necessary 
to produce an adverse apical response may 
depend on the baseline response, and it could 
reasonably be the case that no single amount 
of perturbation of a biochemical or genomic 
response will be without risk for all members 
of a population. A recent NRC committee, 
the Committee on Improving Risk Analysis 
Approaches Used by the U.S. EPA, took this 
view (NRC 2008), concluding that neither 
cancer nor noncancer effects necessarily have 
thresholds and recommending risk assessment 
methods for both cancer and noncancer that 
assume that there is no threshold of exposure 
below which no individual is at risk.
Second, the envisioned in vitro assays will 
have limited sensitivity. It will not be pos-
sible to confirm that a particular pathway has 
not been perturbed, but only to set statistical 
bounds for the potential amount of perturba-
tion. Consequently, every data set is statisti-
cally compatible with some level of response 
at any dose (i.e., no threshold). Because of 
this limited sensitivity, a threshold dose can-
not be proven conclusively to exist (although 
one’s existence could perhaps reasonably be 
predicted from a qualitative understanding 
of underlying mechanisms). Moreover, even 
if a threshold were known to exist, without 
making likely unverifiable assumptions about 
the shape of the dose response, it will not be 
possible statistically to bound the value of the 
threshold away from zero.
The NRC vision includes a key role for 
TP models that would “provide a quantita-
tive, mechanistic understanding of the dose 
response relationship for the perturbations of 
the pathways by environmental agents” (NRC 
2007). However as we discuss in more detail 
below, in order to be realistic, TP models 
will need to be very complex. This complex-
ity will result in large quantitative uncertain-
ties, which make such models particularly 
ill-suited for quantifying small changes from 
baseline responses or estimating thresholds.
These issues are conceptually similar to 
those presently faced in conducting risk assess-
ments using in vivo data. The NRC vision is 
that initially there will be the need for contin-
ued reliance on default approaches like those 
currently applied but that these methods will 
be replaced by methods that rely on TP mod-
els. However, based on the above discussion 
and the more detailed discussion of the limi-
tations of complex mechanistic models that 
follows, without some technical breakthrough 
default methods similar to those presently 
applied to apical responses will still be needed 
for the foreseeable future. In the next section 
we offer some ideas about how these methods 
might develop. To set the stage for this discus-
sion, we first outline methods presently used 
with in vivo data.
The Current Paradigm Based 
on in Vivo Data
The method generally used by the U.S. 
Environmental Protection Agency (EPA) to 
develop a quantitative risk assessment for a 
toxic chemical from experimental animal stud-
ies involves fitting an empirical dose–response 
curve to apical responses to estimate a point 
of departure (POD) defined as an exposure 
corresponding to a specified adverse change 
in the apical response (e.g., U.S. EPA 2005). 
Such a calculation is sometimes referred to as 
a benchmark analysis, and the resulting POD 
as a benchmark dose (BMD) (Crump 1984). 
The change in response used to define the POD 
is set at a magnitude sufficient to allow it to be 
measured with reasonable precision in the bio-
assay (e.g., an increase of 0.1 in the probability 
of an adverse response). The POD is converted 
to a human-equivalent POD using quantitative 
information on the pharmacokinetic differences 
between the test species and humans, if avail-
able, and otherwise using a default method. If 
the response is cancer and there is no compel-
ling evidence that the dose response is non-
linear at low doses, low-dose risk is estimated 
by extrapolating linearly toward zero from the 
point determined by the human POD and the 
specified increase in response. Otherwise, risk is 
not quantified, and the human equivalent POD 
is divided by “uncertainty” or “safety” factors 
that account for various types of uncertainties 
(interspecies differences, human heterogeneity, 
database limitations) to arrive at either a refer-
ence dose (RfD) or, for volatile chemicals, a 
reference air concentration (Figure 1).
Formerly, a NOAEL (no observed adverse 
effect level) was used in place of a benchmark 
analysis to define the POD, and it may still 
be used when data are not available in a form 
appropriate for a benchmark analysis. Neither 
a NOAEL nor a BMD can be considered to 
be risk-free, and at present no factor is applied 
that explicitly addresses this risk.
Elements of a Future Paradigm 
Based on in Vitro Data
Testing strategies. Methods for quantifying 
gene expression are becoming increasingly 
sensitive, and some proteins can now be 
Figure 1. Illustration of an RfD calculation using a benchmark-determined POD.
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detected in attomolar quantities (e.g., Goluch 
et al. 2006). However, sensitivity for detect-
ing proteins, or accuracy in measuring pro-
teins, is only one factor of many that can 
affect the ability to detect the effect of small 
doses. For example, the accuracy with which 
cholesterol can be measured does not drive 
the accuracy of evaluations of intervention 
strategies in large and diverse populations. 
To ensure that exposure standards based 
on in vitro data are protective for a popu-
lation at risk, testing should be conducted 
in cells from a sample of individuals that is 
representative of the genetic diversity and 
disease status of the target population. Cells 
from sensitive subgroups would need to be 
appropriately included. To facilitate routine 
conduct of such testing, libraries of cell lines 
from many different subgroups  (infants, the 
elderly, asthmatics, diabetics, etc.) could be 
set up and maintained.
The in vitro data needed to set an expo-
sure standard for a substance are expected to 
consist of responses from a suite of in vitro 
tests for the identified TPs, measured in cells 
from many different individuals at a num-
ber of different exposure concentrations. For 
example, if the suite of tests for TPs includes 
20–100 tests, and each test is applied to cells 
from 1,000 individuals at 15 different con-
centrations, the data set would consist of 
300,000–1,500,000 data points.
Calculation of a POD. We envision that 
for the foreseeable future any risk assessments 
to support exposure standards developed from 
in vitro data will need to use methods concep-
tually very similar to the approaches described 
above that are currently used with in vivo data 
(Figure 2). In vitro data derived from human 
cells will be used to calculate a POD defined 
as a cellular concentration. A PBPK model 
will be applied to convert an in vitro POD 
to a human POD. The human POD will be 
divided by various factors to produce a human 
RfD, although these factors will need to differ 
both in rationale and in numerical value from 
those presently applied to in vivo data.
The POD could be based on either a 
benchmark calculation or some type of no 
observed response dose similar to a NOAEL. 
Whereas the benchmark approach avoids 
some of the conceptual problems associ-
ated with a no observed response approach 
(e.g., Crump 1984), its use requires select-
ing a dose–response model and positing a 
level of increased risk—decisions not needed 
in calculating a no observed response dose. 
Moreover, with the greater flexibility of 
in vitro methods in selecting exposure levels 
to evaluate and in controlling the sensitivity 
of the tests, some of the advantages offered 
by a benchmark approach may be less impor-
tant. The NRC (2007) applied a bench-
mark approach in its illustrative examples. A 
NOTEL (no observed transcriptional effect 
level) has been proposed for use with gene 
transcription data (Ankley et al. 2006).
With either a benchmark or a no-ob-
served-response approach, decisions will be 
required regarding what in vitro responses to 
account for in their calculation. Should they 
be protective against any change, or should 
some biochemical changes be considered to 
be adaptive and nonadverse? Also, it may not 
be straightforward to extract a POD from the 
large amount of data projected to be gener-
ated. If a large number of pathways require 
testing, false positives could be a serious prob-
lem. Decision rules will be needed to deal 
with these issues.
In vitro testing has an advantage over 
what is typically the case with in vivo testing 
in that replicate cells from each individual 
can be tested at each concentration, so that 
each individual can serve as its own control. 
This permits more realistic models to be used 
in POD calculations, such as ones that allow 
for the amount of change in response from 
background to depend upon an individual’s 
background response as well as exposure.
We do not foresee a useful role for quan-
titative estimates of low-dose risk obtained 
by extrapolating downward from the POD. 
An extrapolated risk of a change in biochemi-
cal, genomic, or cellular end point would be 
much more difficult to interpret than the risk 
of an adverse apical end point. Although con-
ceptually a change in a biochemical end point 
could be translated into an increase in apical 
risk using biologically based dose–response 
(BBDR) models of downstream processes, 
as explained in more detail in a following 
section, developing reliable models for this 
purpose will be extremely difficult.
Uncertainty factors. We suggest that 
one factor should be applied to the POD to 
account for the severity of the downstream 
apical end point. This would allow responses 
in pathways leading to life-threatening dis-
eases to be regulated more stringently than 
those leading to less serious apical end points 
(e.g., cancer vs. a 5% change in liver weight).
Uncertainty factors should also reflect 
what is known about the quantitative rela-
tion between the in vitro end point and the 
apical adverse effect. For example, suppose 
the POD is defined as the in vitro concentra-
tion corresponding to a 10% increase in Nfr2 
pathway activation. Ideally, some quantita-
tive notion of the downstream consequences 
of a 10% increase in this pathway should be 
incorporated into the selection of the uncer-
tainty factors. At this point we do not know if 
such relationships can be reliably quantified. 
It seems likely that uncertainty factors will 
need to be developed by consensus based on 
a qualitative understanding of the mode of 
action of the toxic substance and the poten-
tial shape of the dose response for this mode 
of action. Although it has been proposed 
that BBDR models can eventually be used 
to quantitatively link biochemical and cellu-
lar responses to apical effects (Conolly 2009; 
Rhomberg 2009), as discussed in the next 
section, it appears that it will not be possible 
to develop such models from TP testing data 
in the foreseeable future.
The POD may be calculated from the 
“most sensitive end point,” which possibly 
could be the in vitro response for which a sta-
tistically clear perturbation is seen at the lowest 
concentration. However, different end points 
may differ in their effect upon the apical 
response even though they have similar dose  Figure 2. Comparison of current and envisioned risk assessment paradigms.
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responses. If there were sufficient understand-
ing of the downstream effects of different end 
points, such differences in sensitivity could be 
accounted for by defining different uncertainty 
factors for different in vitro end points.
In the current risk assessment paradigm 
based on results in whole animals, factors such 
as polymorphisms, and preexisting diseases 
are generally treated empirically through the 
application of uncertainty factors. However, 
with in vitro data it may be possible eventually 
to account for such factors directly through 
the selection of the population of cells for 
testing. For example, unique risks to persons 
with preexisting disease or certain polymor-
phisms could be accounted for by including 
cells from such persons in the in vitro assays.
Role of mechanistic models. Two types 
of mechanistic models have potential appli-
cation in the NRC vision. BBDR models 
describe biological processes at the cellular 
and molecular level to link external exposure 
to an adverse apical response. TP models link 
cellular concentrations of toxicants to predic-
tions of perturbations of TPs at the cellular 
level but do not model apical responses (NRC 
2007). Both types of models will typically 
involve complex mathematical formulations 
and require estimates of a number of biologi-
cal parameters as inputs.
Experience to date with complex mod-
els developed from in vivo data can assist in 
evaluating the potential uses and limitations 
of such models derived from in vitro data. 
Whereas BBDR models based on in vivo data 
have proved useful in elucidating mechanisms 
of action of toxic chemicals and identifying 
knowledge gaps, they have not proved to be 
useful in estimating low-dose risks in the range 
of risks required for setting exposure standards 
(e.g., 10–3 and lower). There are several reasons 
for this. In order to link exposure with risk of 
an adverse apical response in a BBDR model, 
at least one of the intermediate variables in 
the model (e.g., a cellular response) must be 
a function of external exposure, generally 
through a PBPK model. The dose response of 
such an intermediate variable is usually mod-
eled empirically, making the resulting esti-
mated risk of the apical response subject to the 
same uncertainties as direct empirical model-
ing of the apical response itself.
This problem is exacerbated by other prob-
lems inherent in complex models, including 
variation introduced by inability to measure 
different intermediate responses in the same 
individuals, uncertainty in the relevance of 
measurements to the mechanism in question, 
and uncertainty as to whether the mechanism 
being modeled is the correct one (Crump et al. 
2010). These problems are particularly acute 
if the toxicant affects multiple and possibly 
mutually interacting intermediate steps in the 
disease process. These complexities manifest 
as uncertainties in estimated risk that often 
are much larger than the small risks that the 
model is attempting to estimate.
Such problems will also be present in any 
BBDR model developed from in vitro data. 
Moreover, they will be exacerbated by inher-
ent limitations in using in vitro data to quan-
titatively predict in vivo responses. The NRC 
committee did not include a role for such 
models in its vision, stating that “the commit-
tee sees BBDR-model development for api-
cal end points as part of a much longer range 
research program and does not see routine 
development of the models from TP testing 
data in the foreseeable future” (NRC 2007). 
However, others (e.g., Conolly 2009) consider 
development of such models from in vitro data 
to be both feasible and important for protect-
ing of public health while avoiding unneces-
sary economic consequences. Although we 
agree conceptually that reliable models would 
be very useful for these applications, we 
also agree with the NRC committee that it 
is highly unlikely that it will be possible to 
develop such models in the foreseeable future.
In contrast to BBDR models, the NRC 
vision included a central role for TP mod-
els that quantitatively model the cellular 
responses in terms of more basic biochemi-
cal and genomic responses. In the schematic 
in Figure 2, TP models would replace both 
the POD and some of the uncertainty factor 
components. Although the examples provided 
by the NRC committee used a POD uncer-
tainty factor approach, this approach was pro-
jected to be used only in the near term while 
the requisite TP models are being developed.
We envision that TP models will prove 
useful in gaining understanding of TPs and in 
designing assays for them. We are less optimis-
tic regarding the ability of TP models to con-
tribute quantitatively to risk assessments that 
support exposure standards. As detailed in the 
discussion that follows, we have two reasons 
for this: First, predictions of small changes in 
responses from complex models are inherently 
uncertain; second, many of the responses that 
such models would be used to predict can be 
measured directly in in vitro assays.
Most of the problems described above that 
complicate efforts to use BBDR to estimate 
low-dose risk will be present in TP models. 
TP models must be quite complex to realisti-
cally reflect the complexity of TPs. For exam-
ple, a model cited by the NRC committee 
for how Escherichia coli protect against heat 
shock (El-Samad et al. 2005) consists of a set 
of 31 differential-algebraic equations with 27 
kinetic parameters, data for many of which 
are not yet available. Even if such a complex 
TP model is correctly specified, uncertainty in 
parameters can have a very high leverage on 
estimates of low-dose response, so what one 
gains from introducing more biological realism 
through the modeling will likely be lost in a sea 
of statistical uncertainty (Crump et al. 2010). 
However, this does not mean that a TP model 
is useless for risk assessment. A TP model 
could be used to evaluate theoretically various 
stages in a TP that are exposure dependent and 
important to the apical response and thus play 
an important role in helping to identify critical 
in vitro end points that can serve as biomarkers 
for apical end points.
For TP models to be used quantitatively 
in risk assessment, they must be dose–response 
models; that is, they must model the down-
stream cellular response, not just in terms of 
upstream genomic or biochemical responses, 
but mechanistically as a function of the cel-
lular concentration of the toxic substance or 
its metabolites. Whether such modeling will 
be possible at all and, if so, whether it can be 
implemented with sufficient accuracy are open 
questions. For example, the heat shock model, 
even though already quite complex, does not 
include modeling of the dose response resulting 
from the perturbation of this system by a toxi-
cant. The same is true of the other TP mod-
els cited as under development by the NRC 
committee. Without this critical component, 
genomic responses to toxic insults will need to 
be modeled empirically and will be subject to 
the limitations inherent in such modeling.
These limitations will be magnified if, as 
will likely be the case, a number of genomic 
or biochemical responses must be modeled, or 
the dose response of the cellular variable being 
modeled depends in a complicated way on the 
dose responses for the biochemical or genomic 
responses, for example, if the cellular response 
is very sensitive to small differences in these 
responses. Such models will also be subject 
to limitations stemming from difficulties of 
in vitro systems in capturing the complexity 
of responses in whole animals, for example, 
complexity resulting from intercellular signal-
ing pathways that are present in vivo but are 
not present, or are present in a modified form, 
in vitro.
The cellular responses that TP models 
would be designed to predict may be amenable 
to direct measurement. In fact, having such 
data may be necessary to fully implement a TP 
model, just as data on the apical response have 
been used in the development of BBDR mod-
els for in vivo responses, (e.g., Conolly et al. 
2003). Given the problems inherent in com-
plex models that we have discussed, and the 
relative ease with which in vitro data can be 
generated, we foresee measurements of critical 
in vitro end points playing a more important 
role than predictions from TP models in risk 
assessments based on in vitro data.
Rather than basing a risk assessment on 
predictions of a cellular response made from a 
TP model, an assessment could be based more 
directly on upstream responses that would Crump et al.
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otherwise serve as inputs to a TP model. In 
other words, once the dose-related biochemi-
cal and genomic steps in a pathway have been 
identified, it may be more feasible to work 
directly from these inputs rather than from 
predictions of downstream consequences 
obtained from TP models.
Once developed, a TP model would 
quantitatively predict some downstream cel-
lular response, such as apoptosis, as a func-
tion of gene expression or other biochemical 
end points. As is true with any such model, 
such predictions will be subject to statistical 
uncertainty. Consequently, just as the NRC 
committee proposed benchmark methods for 
dealing with statistical uncertainty in measured 
responses, similar methods would be needed to 
deal with uncertainty in predictions from TP 
models. Thus, even if successfully developed 
and employed, TP models would not obviate 
the need for POD-type methods.
Conclusions
We have described our vision of how in vitro 
data will be used in the future in the con-
duct of quantitative risk assessments for toxic 
chemi  cals. We foresee that these data will be 
used in ways that are conceptually similar to 
the POD uncertainty factor approach pres-
ently used with in vivo data: In vitro data 
will be used to determine PODs using either 
BMD- or NOAEL-type approaches, to which 
uncertainty factors will be applied. Calculation 
of PODs will be much more complicated than 
similar calculations using in vivo data because 
of the multiplicity of TPs and large amount of 
data that are expected to be available on each 
pathway. Determining suitable uncertainty 
factors to apply to these PODs will require 
larger inputs of scientific judgment than those 
based upon in vitro data because of the uncer-
tainty in the quantitative relationship between 
the cellular response upon which the POD will 
be based and a downstream apical response.
For these methods to be used by regula-
tory agencies, numerous decision rules will be 
needed to guide methods for calculating PODs 
and selecting uncertainty factors. In the past, 
incorporating such approaches into regulatory 
decisions has been a very time-consuming and 
contentious process. Even though we are in 
the very early stages of developing a risk assess-
ment paradigm based on in vitro data, it is not 
too early to begin thinking of what changes in 
environmental laws and institutional arrange-
ments will be needed to facilitate this process 
(Elliott 2009).
We recognize that the uncertainty-factor–
based approach is not the most comprehen-
sive approach and that selecting appropriate 
uncertainty factors will be a difficult and likely 
confrontational process. However, these prob-
lems are also inherent in current methods. 
There is a critical need to move forward in 
using the new data as soon as possible. Even 
if more comprehensive methods eventually 
emerge, progress in the foreseeable future is 
most likely to occur using simpler methods 
like those outlined in this commentary.
One facet of the NRC vision that we 
believe has been given insufficient scru-
tiny is the role of quantitative TP models 
in risk assessment. The vision assumes that, 
once such models are developed, they will 
replace POD–uncertainty factor approaches. 
However, details of how this will come about 
have not been clearly articulated. Even if this 
optimistic goal were to be realized, it would 
not negate the need for POD–uncertainty fac-
tor approaches, because every model is limited 
in its predictive ability. However, we think 
the goal is unlikely to be realized in the fore-
seeable future. Such models typically model 
downstream responses as a function of more 
basic biochemical and genomic end points 
but do not incorporate the critically needed 
modeling of the dose responses of these end 
points. In addition, complex models of this 
type, even if correctly specified, are fraught 
with statistical uncertainty, which severely 
limits their usefulness in making estimates 
of small changes in response that are needed 
in risk assessments to support exposure stan-
dards. Because of these difficulties, and also 
because of relative ease of collecting in vitro 
data, we expect that measurements of critical 
in vitro responses will prove more useful than 
will predictions from complex models.
We recognize that we may be overly pes-
simistic in our assessment of the utility of TP 
models, and we encourage continued research 
in this area. At the same time, we also urge 
more careful consideration of the role of TP 
models in quantitative risk assessment and the 
likelihood of their success in fulfilling this role.
Use of in vitro data in risk assessment has 
great promise toward allowing chemicals to 
be tested more quickly and cheaply and for 
reducing or eliminating the need for subject-
ing animals to toxic insults. It is our hope that 
the bar for accepting approaches based on 
in vitro data will not be set too high. In view 
of the numerous serious limitations of current 
approaches, results from these methods based 
on whole-animal data should not be held up 
as gold standards. This point is particularly 
important considering that almost all whole-
animal data are obtained from high doses that 
may operate through different sets of TPs than 
do low doses.
The discussions presented in the article are 
offered to help facilitate the kinds of thinking 
and discussion that will be required to bring 
these modern in vitro methods into general 
use for setting exposure standards for chemi-
cals. Large commitments of resources will be 
required to develop and validate the in vitro 
tests that will be needed. These resources can 
be allocated most efficiently if there is a clear 
vision of how these tests will be applied in set-
ting exposure standards. There is, of course, 
the possibility of a technical breakthrough 
that will render obsolete the methods we have 
outlined here. Even if such a breakthrough 
does eventually occur, we believe that meth-
ods like those we have discussed here will be 
required for some time.
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